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Abstract
Nano and micro particles have steadily grown in interest for modifying the mechanical
and biological properties of synthetic bone composite structures. Nano and micro sized calcium
phosphates are of interest because of the osteoinductive behavior of calcium phosphate.
Engineered composites incorporating polymers and ceramics, such as poly l-lactic acid
(PLLA)/β-TCP, for bone tissue regeneration have been well investigated for their proliferative
and osteoinductive abilities. Only limited research has been done to thoroughly investigate the
effects of various sized β-TCP particles on human mesenchymal stem cell behavior. Foreign
bodies are known to elicit an inflammatory and cytotoxic response and several nano-particles are
known to elicit cytotoxic and pro-inflammatory responses of mesenchymal stem cells. In this
study, the modulation of adult human adipose-derived mesenchymal stem cell (hASC) behavior
exposed to β-TCP, as functions of particle size, content and composition in a polymeric-ceramic
scaffold system was investigated. The objectives of this work include the development and
characterization of monolithic 3-D polymeric-ceramic structures using a modified unidirectional
fabrication technique to investigate the cytotoxic, pro-inflammatory and osteogenic potential of
PLLA-β-TCP composite on adult human stem cells. Characterization of PLLA-β-TCP
composites showed that increasing β-TCP content the compressive strength decreases. Viability
of hASCs over a 7 day exposure study showed increasing cytotoxicity with respect to increasing
particle concentration regardless of size, although acute (24hr) cytotoxicity was more influenced
by size. qPCR was used to measure the pro-inflammatory (IL-6) expression as well as early
osteogenic differentiation (hALP). Results suggest there is a modulation in stem cell behavior as
a function of β-TCP particle size, concentration and composite system.
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Introduction
1.1. History of Bone Regeneration
Bone-grafting plays a prominent role in the treatment of non-unions and delayed unions,
joint arthrodesis, the filling of bone cavities, and the replacement of bone lost due to trauma[1].
Today, bone grafting is one of the most frequently performed procedures in repair of damaged,
defective tissue with more than 2.2 million procedures a year [2]. The number of procedures has
grown considerably from 1668 with the first described bone grafting procedure: an injured
soldier, as a result of war, received a cranial defect which was successfully repaired using a
dog’s skull [3]. Other notable procedures (dates) of note are: Fred Albee, MD, first described
autologous bone grafting for spinal fusion (1915); Swedish surgeon Levander, conducted one of
the first demonstrations of osteoinduction by injecting bone extracts into muscle, noting bone
production (1930); Marshall Urist, MD, identified a compound (bone morphogenic protein, or
BMP) that was noted to have osteoinductive potential (1965) [3] . These events and others were
the building blocks that have aided in the advancement of bone grafting.
Bone, when damage is confined to 1mm or less, has remarkable healing abilities, but
more persistent critical size defects that are greater than 1cm [4], often require grafting or similar
procedures to initiate proper healing [5]. Addressing these critical sized bone defects is a
significant and ongoing problem in orthopedics [6]. The standard, preferred form of grafting is
autologous grafting, which involves harvesting a portion of bone from an intact skeletal location
of the patient and transplanting into the defect site. However, donor site morbidity, limited bone
supply, structural differences limit the use of this technique [4]. Allografts, grafts taken from a
different individual, provide additional source of grafts, but immunological response and disease
transmission are of concern [7]. Additionally, prosthetic or synthetic materials have proven to
have limited effectiveness due to unpredictable graft absorption, infection, structural failure and
1

unsatisfactory aesthetic outcomes [4]. Synthetic bone scaffold analogs address many of these
concerns by providing high volume material free of diseases and immunogenic biological
material [8]. Biodegradable polymeric scaffolds, seeded with living cells, could be used as an
alternative to traditional tissue graft material[9], potentially help to bridge the widening gap in
supply and demand [8, 10].
1.2. Engineered Bone Scaffolds
A current tissue engineering paradigm combines cells, biomaterials, and environmental
factors that facilitate cell proliferation, growth, and differentiation. The approach to regenerative
bone tissue engineering consists primarily of three constituents: (1) cells, (2) biomaterials and
(3) scaffolds. Recent research focuses on the interaction of the constituents as a system.
The principal method of engineering bone involves growing relevant cell(s) in vitro into a
suitable three-dimensional (3D) scaffold followed by in vivo implantation. Engineered bone
substitutes should satisfy four prerequisites for bone healing: (a) cells must have osteogenic
potential; (b) an osteoconductive matrix; (c) an osteoinductive stimulus; (d) a mechanically
stable environment [11]. The scaffold is a temporary or semi-permanent structural substitute
preferably mimicking the biological, chemical, and mechanical characteristics of native bone. A
bone scaffold must be capable of promoting osteogenesis, osteoinduction, and osteoconduction
to actively facilitate bone formation [12].
Ideally, a scaffold should be biocompatible, biodegradable, porous, and mechanically,
chemically, and biologically compatible to the local tissue’s environment. Scaffolds provide the
necessary 3D environment for cells to proliferate and assemble into tissue [13]. Since organs are
an assembled unit of various cell types and each with their own requirements, engineered
scaffolds would have to meet the needs of each cell type with the correct balance between the
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biological and physical properties of the scaffold material to suit each cell type [14]. There are
several properties a scaffold should possess (Table 1.1), although these properties may need to be
optimized depending on the tissue in need of repair. Optimization of engineered bone substitutes
allows for the creation of absorbable and bioactive scaffolds with tailored physical and
mechanical properties. Moreover, materials can be engineered in such a way that their absorption
rate in the body matches the formation rate of new tissue[15].
Table 1.1. Six Criteria for Biodegradable Polymers Used for Tissue Engineering, Adapted [16]
1. Promote adhesion and growth
2. Degradation products does not elicit inflammation or cytotoxicity
3. Processable into 3D scaffold
4. Generate highly porous and interconnected scaffold
5. Fully absorbable
6. Degradation rate should match tissue regeneration time
Several fabrication techniques have been used in the creation of bone scaffolds such as
electrospun fibers[17-19], solvent or particle leaching[20], phase separation, emulsion[21], and
hydrogels[22, 23]. Depending on the process, various attributes such as pore size, porosity, and
architecture may be achieved [24]. Process design considerations should include promoting
cellular infiltration, growth, and differentiation toward new bone formation [10], but scaffold
properties such as pore geometry, size, interconnectivity, and spatial distribution depend on the
fabrication process rather than process design[13]. Creating a suitable construct that has adequate
porosity and pore structure has long been a challenge in obtaining a ubiquitous distribution of
cells throughout the entire 3D scaffold volume[25]. The micro- and macro-scale morphology of
the structures plays a vital role in the adhesion, differentiation, and proliferation of cells[7, 26].
A suitable macro porous structure is necessary to obtain good implant incorporation through
rapid vascularization and bone progenitor ingrowth[7]. Minimal pore size for bone ingrowth is at
least 100 μm [27, 28], but several papers demonstrate that larger pore sizes > 300μm improve
3

bone formation and vascularization of grafts [28, 29].Adequate porosity and structure are critical,
but mechanical properties are an important requirement for load bearing –bone-tissue scaffolds
[25].
The choice of appropriate scaffold fabrication technique and the biomaterial are largely
dependent on the tissue application. For bone tissue engineering, a technique that produces a
scaffold with large pores, highly interconnected, and adequate mechanical properties is desired.
Thermally induced phase separation (TIPS) method enables the production of foams which
exhibit pore anisotropy, which may be controlled to enable the fabrication of scaffolds with
tailored porosity appropriate for bone formation [30]. A scaffold prepared using thermally
induced phase separation (TIPS)[15, 31-38]

will have a very high porosity, < 97%, with

moderately sized pores, < 200 µm, and a high degree of pore interconnectivity[24] appropriate
for bone ingrowth and formation.
As the scaffold is degraded, the invading cells deposit their own extracellular matrix
(ECM) molecules and eventually form 3D structures that closely mimic the native tissue
architecture[13] and while replacing the scaffold structure. The structure and material properties
of biomaterials are known to modulate ECM signals for directing proliferation and
differentiation of cells [39]. The absorptivity of bone ECM components is known to influence
the adhesion and osteogenic capacity [40] creating an environment closely mimicking natural
bone tissue.
To be most effective the degradation of a degradable polymeric scaffold should closely
match the cell’s proliferation and growth rate to ensure proper tissue formation [24].
Biodegradation is typically due to hydrolytic or oxidative enzymatic action [41]. Polylactides
such as PLLA are readily hydrolyzed in the presence of water and auto-catalytically degrade into
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lactic acid which is a constitutive component of most tissue normally present in the body. Lactic
acid is metabolically digested during the tricarboxylic acid cycle and is excreted as water and
carbon dioxide[42]. The release of degraded polylactide, lactic acid, into surrounding cells and
tissue results in a lowering of the pH and the inception of inflammatory reactions [24],
potentially hindering tissue formation.

1.3. Biocompatible, Biodegradable Materials for Bone Engineering
Material composition and morphology play a vital role in a scaffold’s ability to regenerate
tissue. Materials used in scaffold fabrication include polymers (natural and synthetic), ceramics,
and metals [42]. Considerable research has gone into the development and characterization of
biodegradable, biocompatible materials. Biodegradable synthetic polymers offer a number of
advantages over other materials for developing scaffolds in tissue engineering. Key advantages
include the ability to tailor mechanical properties and degradation kinetics to suit various
applications [42]. Synthetic polymers can potentially be designed such that they degrade in place
to be replaced by native tissue thereby regaining normal tissue and functionality [31, 42].
Biodegradation is an additional tunable aspect of polymer composites[43].
To be clinically relevant, a biomaterials approval by the FDA is based on the materials nontoxicity, sterilizibility, and effectiveness [41]. Biocompatibility not only pertains to the materials
ability engender an appropriate host response, but its complex interaction with local cells and
tissue[16]. Biocompatibility is a highly desirable aspect of biomaterials, although most clinically
used biomaterials lack optimal biocompatibility[15].The success of a biomaterial in the body
depends on many factors such as bioactivity, design, and biocompatibility of that material, as
well as other factors not under control of the engineer, including the technique used by the
surgeon, health, condition and activities of the patient [44]. Improved performance is important
5

to engineers, but the needs of clinicians are for the materials to be reasonably priced, easy to use,
and good clinical outcome, regardless of composition [45]. Although work to improve
biomaterial biocompatibility is ongoing, incorporation of bioceramics, namely calcium
phosphates[46, 47], and extracellular matrix (ECM) components of bone (fibronectin,
vitronectin, collagen I and IV, laminin, etc) [14]

into synthetic bone scaffolds improves

osteoconduction and osteoinduction.

1.4. Polymer/Ceramic Composites for Bone Tissue Engineering
Numerous polymer constructs, natural and synthetic, have been used as structural
materials for bone scaffolds. A notable branch of the synthetic polymers are synthetic polyesters.
The stability of polyesters (aliphatic and aromatic) and the mechanical and biological traits [48]
they possess makes them very suitable biodegradable polymers for use in bone repair research.
Several polyesters have been. Commercialized synthetic polyesters such as poly lactic acid
(PLA), poly(lactide-co-glycolide) (PLGA), and polycaprolactone (PCL) [49] have received
much attention as suitable biomaterials in synthetic bone composites [50-54] are commonly
used biomaterials for bone tissue regeneration because of their tailorable mechanical properties
and ease of fabrication using molding, casting and foaming techniques resulting in a wide range
of possible pore morphology and chemical functional groups conducive to tissue in-growth [42].
Polyesters generally do not possess the necessary chemical features as they are often
hydrophobic and degrade via self-catalysis [55]. Generally biocompatible, polyesters often lack
osteoinductive capability for bone formation [4, 15] and are most often combined with natural
ceramics (hydroxyapatite (HA) and tricalcium phosphates (TCP) that aid to promote cellular
adhesion, bone growth and help reinforce the polymeric scaffold [27, 53, 56-60]. PLLA and βTCP will be discussed in detail in subsequent sections. Synthetic polymers are inherently
6

hydrophobic and do not easily promote cell adhesion, and the addition of HA and/or TCP
ceramics improves adhesion and proliferation [46] (Figure 1.1).

Figure 1.1. Composites with increasing β-TCP concentration show increasing cell density [46]
1.4.1. Poly-l-Lactic Acid (PLLA)
Lactide is the cyclic dimer of lactic acid, which exists as two optical isomers, D and L; L-lactidethe naturally occurring isomer [55]. L-lactic acid is a metabolic intermediate resulting from the
fermentation of carbohydrate containing food and agricultural by-products [43]. The usage and
interest in poly-lactic acid, D and L, ranges from biomedical research to industrial applications.
Recent research has largely focused on polylactic acid (PLA), particularly the L-confirmation,
poly l-lactic acid (PLLA). This aliphatic polyester is FDA approved for medical use and
commonly because it is readily biocompatible and biodegradable [43, 61]. PLLA is often used
because it has adequate material, chemical, and biological properties for in vitro and in vivo
scaffold applications [16, 49, 52, 55, 62]. Lactic acid and other low molecular weight (MW)
aliphatic polyesters are very compatible with each other, [43]

allowing for a blending of

properties tailored to specific tissue applications. The first commercialized biodegradable
polymer biomaterials were copolymers of lactic acid and glycolic acid. Tunable material
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properties of polyesters in combination with calcium phosphates are very often used to improve
cellular adhesion and induce bone formation.
Lower molecular weight polymers possess better compatibility, while higher molecular
weight polymers inherently possess appropriate mechanical properties. Low molecular weight
PLLA is obtained by the thermal dehydration polymerization of l-lactic acid [43], whereas,
synthesis of higher molecular weight PLLA is more involved. For bulk polymerization, the most
effective mechanism is coordination ring opening polymerization [49] with a suitable catalyst
(aluminum, tin, zinc, titanium) to produce higher molecular weight PLLA [43, 49, 55, 62] with
useful properties. Tin catalysts are often used because it is available and effective and can be
used for large scale production of PLA [43]. Garlotta et al [62] provides further review of PLLA
and its synthesis processes.
1.4.2. β-Tricalcium Phosphate (β-TCP)
β-TCP and other calcium phosphates have dominated regenerative bone research and
with good reason. By mass composition, bone consists of 70% inorganic, apatite, and 30%
organic, collagen, so the use of ceramics in synthetic bone composites, then, is easily
understandable[5]. Calcium phosphate ceramics as bone substitutes dates back more than 30
years where it was used in dental implantation[47]. Calcium phosphates have been of increasing
interest in combination with polyesters (PLA, PLGA, and PCL) to serve as synthetic bone-like
structures aiding in bone repair [27, 44, 53, 56, 57, 60, 63]. TCP [Ca3(PO4)2] and hydroxyapatite
(HA) [Ca10(PO4)6(OH)2] are the most extensively used calcium phosphates [64]. The brittle
nature of the calcium phosphates limits their effectiveness as bone substitutes, but incorporating
calcium phosphates and polymers, the synthetic structures closely mimic natural bone and
stimulate ossification[14, 64, 65]. Calcium phosphate ceramics exhibit little toxicity to tissues,
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bioresorption and osteoinductive properties [64]. Calcium phosphates have substantial
biocompatibility and promote osteoconduction [5, 47]. Calcium and phosphate ions are
important components during the mineralization phase of the ossification process. This
osteoconductive property is due in part to the absorbance of fibronectin and vitronectin, ligands
that mediate cellular adhesion and osteoblast precursors.
Traditionally HA has been widely studied, but β-TCP has grown increasing popular for
bone repair due to its superior biodegradation and absorption compared to that of HA [5]. As
with polymeric scaffolds tuning by the blending of polymers, so are the properties of calcium
phosphates. Biphasic ceramics consisting of HA and β-TCP are shown to have improved
bioactivity and degradation rates relative to HA or β-TCP alone [14]. Incorporation of HA and βTCP allow composites to be tailored to have the desired degradation and absorption kinetics and
serve to buffer the acidic absorption by-products of polymer degradation and could thereby
decrease the deleterious cell response[28].
To facilitate bone regeneration, β-TCP and other calcium phosphates are frequently used
as the base of synthetic scaffolds. Calcium phosphates have repeatedly demonstrated the ability
to support bone formation [5, 24, 39, 60, 64]. Mesenchymal stem cells osteoblastic
differentiation and osteogenesis seeded within calcium phosphate matrixes are well studied and
reviewed[39].
Bioceramics such as HA and β-TCP can provide a suitable osteoinductive environment
while providing a suitable substrate for cellular adhesion and proliferation and also act as an
enabling composite structure to induce osteogenesis [5, 7, 9, 39, 40, 47, 64, 66]. Several papers
have described the osteogenic effects of these ceramics in pure form or as components of
polymeric composite structures, for inducing increased osteoconductivity and differentiation [5,
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29, 40, 47, 58, 66]. The ceramics are unique in that they are structurally similar to the mineral
phase of bone [5], bond to bone and increase the rate of tissue formation [64]. Because of the
abundance of literature on the osteogenic and proliferative impacts of calcium phosphates, this
paper will compare the induction of cytotoxicity and immunomodulation of ASC by β-TCP
particles (nano and micro) in solution and in composite scaffold structures.

1.5. Stem Cells
Adequate cell source in terms of number and proliferative potential are a limiting factor
in regenerative medicine. A sustainable cell sources is a critical component to the advancement
of tissue engineering and regenerative medicine, and stem cells are a valuable source. Stem cells
are increasingly growing in their relevance to tissue engineering and regenerative medicine as
promising prospects for regenerative medicine. Stem cells, whether derived from embryos,
fetuses, or adults, seem poised to dominate the next frontier of human regenerative medicine and
cellular therapy [14].
The use of embryonic stem cells (ESC), which hold the potential to differentiate into
every cell type in the body and are believed to be able to proliferate indefinitely, is very
controversial. Ethical concerns and domestic legal restrictions around the use of embryonic
derived stem cells have driven the use of adult derived stem cells as an alternative source [4].
Adult stem cells, a less controversial source of stem cells, hold comparable pluripotency to that
of ESCs. Adult derived stem cells have been isolated from every major tissue and organ of the
body [14] and this present the possibility to regenerate these areas if damaged. Over the last 15
years, major advances have been made in the isolation, cultivation, and induction of
differentiation of stem cells from various sources [14]. Stem cells relevance is still limited by
supply, which is a predominate limitation of treatments to address present day tissue/organ
10

failure. Combining the advances in stem cell technologies and biomaterials, tremendous strides
have been made in improving the efficient use of the limited cellular supply and providing a
therapeutic modality that promotes cellular growth and differentiation.
1.5.1. Human Adipose-derived Stem Cells (hASCs)
Human adipose-derived stem cells (hASCs) are an attractive cell source considering that
they are multipotent (osteogenic, chondrogenic, myogenic, adipogenic and neurogenic) [4, 14,
39, 40, 67, 68] , proliferate quickly, and easily assessable [40, 68]. Use of autologous adiposederived stem cells for tissue regeneration will minimize adverse immunological effects
commonly associated with analogous therapies. hASCs may also serve as an alternative to bonemarrow derived stem cells (BMSCs). Possessing approximately the same surface markers and
differentiation capacity, hASCs are becoming more favorable over bone-marrow derived cells
(BMSCs) due to the less invasive harvesting procedures for adipose tissue.
In recent years, in part due to escalating interest in cosmetic procedures, human adipose
derived mesenchymal stem cells have become an attractive source of cells. With more than
400,000 liposuction procedures each year in the U.S. [67] , human adipose stem cells (hASCs),
isolated from the lipoaspirate, provides an abundant supply of stems cells with individual yields
of 100ml to 3L of tissue[67] and > 106 cells per 15mL of aspirate [69]. hASCs are advantageous
for tissue engineering applications due to their plasticity allowing formation of various tissues
depending on the scaffold’s components. Using autologous human cells seeded on a poly(D,Llactide-co-glycolide) (PLGA) scaffold, a whole urinary bladder was engineered and reportedly
transplanted successfully in human patient [14].
Several studies have evaluated the differentiation capacity of hASCs when cultured in
polymeric scaffolds both in vitro and in vivo [14, 70, 71]. Santiago et al investigated hASCs
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attachment on modified poly-caprolactone surfaces [14, 70]. Definite osteogenesis was
demonstrated with hASCs seeded into HA/TCP/collagen composites when implanted in severe
combined immunodeficient (SCID) mice [71]. Side-by-side comparison of BMSCs and hASCs
in collagen or β-TCP scaffolds showed no distinguishable difference in the osteogenic capacity
between the two either in vitro or in vivo [14]. Lui et al (2008) [40] studied the proliferation of
hASCs seeded onto akermanite and β-TCP disks with hASCs for 1, 4 and 7 days and reported
good compatibility with little cytotoxicity.

1.6. Nano-particles: Toxicity and Pro-Inflammation
1.6.1. Wear Debris Toxicity
When engineering a replacement for bone, metallic implants are an obvious choice for bone
repair due to the materials predictable mechanical properties. However, the mismatching of
metal mechanical properties with local bone tissue often results in osteoporosis, and requires a
corrective procedure to remove the implant [43]. Particulate wear debris from joint implants (e.g.
PMMA, ceramic, metal, or polyethylene) can initiate a biological and immunological response,
involving macrophages and IL-1, IL-6, IL- 10, and TNFa activation [11].
1.6.2. β-TCP Toxicity and Pro-inflammation
Nano and micro particles have steadily grown in interest for synthetic bone composite
structures. Nano and micro sized calcium phosphates particle especially are of interest because of
the osteoinductive behavior of calcium phosphate. However, several nanoparticles are reportedly
described as being toxic to mesenchymal stem cells [72, 73]. The relationship between the size
and type of biomaterials and tissue reaction has not been clarified completely [64].

Size

dependent cytotoxicity of gold nanoparticles was examined by varying the size 0.8 to15 nm [74];
1-2nm particles were highly toxic and larger particles comparatively nontoxic . It is known that
12

the morphology, size, and surface of structures play a very vital role in the adhesion,
differentiation, and proliferation of cells [7, 26]. Liu et al (2008) [40] examined hASCs viability
on Akermanite and beta-tricalcium phosphate (β-TCP) disks by measuring lactate dehydrogenase
(LDH) leakage at 6, 12, 18 and 24 h after seeding on each disc type and results reflect a steady
increase in LDH release over time from both disk types.
Reportedly, calcium phosphate ceramics exhibit limited toxicity to tissues [7, 75],
however, when used as carriers for osteoinductive factors, inflammatory and immunologic
reactions have been reported [64]. The foreign-body response of calcium phosphates is variously
described as: (1) calcium phosphate ceramics do not elicit a foreign-body reaction [8] and are
well tolerated by host tissues; and (2) its presence elicits a foreign-body response [7] . Cells and
surrounding tissue respond adversely to ceramic/polymer composites with a decrease in
bioactivity from the release of toxic breakdown elements into the surrounding tissues [64]. As
the construct degrades, the massive release of acidic degradation and absorption by-products
results in inflammatory reactions [24, 28].
There are problems associated with inflammatory and immunologic reactions and disease
transmission when used as carriers for osteoinductive factors. TCP is considerably more
biodegradable than HA, which does not decompose in the body [64]. However, bioceramics
presence is known to elicit a foreign body response [7]. Previous studies have been done on
hASCs to determine the pro-inflammatory cytokine profile [46, 76]. Kilroy et al [76] showed that
lipopolysaccharide exposure, hASCs increase their secretion of pro-inflammatory (interleukins 6,
8, and 11, tumor necrosis factor a) cytokines based on ELISA and RT-PCR . Aunoble et al [46]
performed in vitro evaluation of inflammatory potential of human osteogenous cells exposed to
PLLA/TCP composite materials containing 0, 30, and 60 (w/w)% TCP with LPS as the positive
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control and showed there was an increased proliferation and synthesis of the extracellular bone
matrix with increasing TCP percentages.
Much has been made of the proliferative and osteoinductive capabilities of β-TCP
particles, but not in regards to particle size and concentration. The goal of this work is to study
the modulations of mesenchymal stem cell behavior within cell/particle and cell/composite
systems as functions of particle size, concentration, and exposure time by measuring cytotoxicity
(metabolic activity) and pro-inflammatory cytokine expression.

14

Materials and Methods
2.1. Materials
PLLA ((C3H6O3)n, average Mw 100,000-150,000, inherent viscosity 0.9-1.2 dL/g) (Sigma
Aldrich) was used as received. Β-TCP (Ca3O8P2), sintered micron and unsintered nano sized
powders (MW = 310.18) were used as received (Sigma Aldrich). 1,4 dioxane, anhydrous 99.8%,
(Sigma Aldrich) was used as the solvent in the scaffold fabrication.
2.2. Scaffold Fabrication
Poly-lactide and bioceramics composites have been developed using TIPS [15, 36-38,
50]. Scaffolds generated using TIPS have shown to support migration, adhesion, spreading and
viability[30]. TIPS was used along with unidirectional freezing to create novel PLLA/β-TCP
composite monolithic scaffolds[36, 50].
Scaffolds were prepared according to a modification of the method previously described
by Kim et al[36]. PLLA/β-TCP composites were all generated at a 7 wt. % concentration with
varying ratios of PLLA:β-TCP (90:10, 70:30, 40:60). First, PLLA was dissolved completely in 1,
4 dioxane while mixing at 50°C. After dissolution, the corresponding size and amount of
particles were added and thoroughly mixed. The mixture was allowed to cool to room
temperature and then transferred to glass shell vials (O.D. x H: 15 x 45mm). The mixture was
unidirectionally frozen by lowering the vials into the vapor region of a liquid nitrogen bath at a
constant rate of 1in/hr. After freezing the mixture completely, the solidified sample was freezedried at -80°C and 0.02 mbar for 48hrs to sublimate the solvent resulting in a highly porous
interconnected scaffold.
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2.3. Scaffold Characterization
2.3.1. Scanning Electron Microscopy (SEM)
Scanning electron microscopy (SEM; JSM-6610LV) was used to investigate the
anisotropy and homogeneity of the composites’ microstructure and to assess the porous
architecture in different regions within the structure. Composite sections were cut using DORCO
ST 300 stainless blades, via continuous downwards slicing to avoid compression damage.
Samples were platinum coated for 120 s using a current of 10 mA then imaged with an
accelerating voltage of 10kV.
2.3.2. Thermogravimetric Analysis (TGA)
Thermogravimetric analyses (TGA) were performed on the composite constituents PLLA
and beta-tricalcium phosphate as well as on composite foams using TA instruments TGA 2950.
Thermo Gravimetric Analysis (TGA) was performed with a heating rate of 10 °C/min under
nitrogen flow. At least three samples for each composite material were analyzed and the results
averaged to determine the thermal and degradation profiles and residual mass. Scans were
performed under nitrogen flow with a temperature range of 0 – 600°C at a rate of 10°C /min.
2.3.3. Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry was used to study the thermal transitions of the PLLA
used in scaffold fabrication using MDSC 2920. The method:

1) 20.00°C to -20.00°C at

2.00°C/min; 2) -20.00°C to 180.00°C at 5.00°C/min; 3) 180.00°C to -20.00°C at 2.00°C/min; 4)
-20.00°C to 180.00°C at 5.00°C/min. By ramping the temperature over the range of -20°C to
180°C at varying heating rates, the thermal transitions was determined; glass transition (Tg),
crystallization temperature (Tc) and melting temperature (Tm).
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2.3.4. Mechanical Analysis
Compression analyses of composite scaffolds were carried out using an electromechanical testing machine (Instron-Model 5960) at a testing rate of 5mm/min and maximum
compressive strain of 50%. 5 composite disk specimens of each PLLA: β-TCP scaffold blends
(90:10, 70:30, and 40:60) with the geometry of 12mm (d) X 3mm (h) were tested. The
compressive strength at the maximum strain (50%) was calculated.
2.3.5. Scaffold Degradation
Scaffold degradation performed on 12mm (d) X 3mm (h) composite disks taken from the
most uniform regions of each respective composite scaffold. Initial weight of the scaffolds
specimen was recorded before sterilization (ethylene oxide). Specimens incubated at 37°C (1
scaffold/15mL centrifuge tube) in 7mL stromal media (Dulbecco’s modified Eagle’s medium
(DMEM), 10% FBS, 1% triple antibiotic solution). Extraction determined by moderate agitation
in a shaker incubator for 1, 5, 15 days. At the end of each time point, scaffolds were trypsinized,
rinsed with distilled water, and freeze-dried for 48 hours. Changes in composite mass and pH
were measured and recorded to observe effects of PLLA/β-TCP degradation. Media containing
scaffold degradation products was stored at 4°C for viability/cytotoxicity assays.

2.4. In vitro hASC Viability Studies with alamarBlue®
2.4.1. Cell Studies
Cell studies were performed using human adipose-derived stem cells (hASCs) of passage
numbers 2 and 3 (P2-P3) (Pennington Biomedical Center). hASCs, passage 0 (P0), were initially
plated at a density of 104 cells/cm2 and were maintained in 150cm2 flasks (BD Falcon, Franklin
Lakes, NJ) with 25mL stromal media (Dulbecco’s modified Eagle’s medium (DMEM/F-12),
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supplemented with 10% fetal bovine serum (FBS), 100 U penicillin, 100ug streptomycin, and
0.25ug Amphotericin) and incubated at 37°C in a humidified 5% CO2 environment.
2.4.2. alamarBlue®: Cell Viability
A fluorescent metabolic indicator, alamarBlue® (Invitrogen) was used for quantitative
viability measurement for cell studies. Viability of cell studies was determined by adding
alamarBlue® at 0.1 volume followed by 2hrs incubation at 37°C. The resulting fluorescence due
to cell metabolism was measured at room temperature on a Wallac Victor2 V 1420-041
Multilabel HTS using an excitation and emission wavelength of 531 and 595 nm, respectively.
2.4.3. β-TCP Cytotoxicity
The effect of β-TCP particles on the proliferation of stem cells was evaluated by treating
cells with varying concentrations of β-TCP particles over time. Cells were seeded at 2.5 x 104
cells/sample (n=3) and incubated for 24hrs to allow for adhesion to plate. After initial 24hr
incubation, media was removed and varying concentrations (wt/vol%) of β-TCP, both micro and
nanoparticles, (2.5%, 2.0%, 1.5%, 1%, 0.5% 0.1% and 0.01%) were exposed to hASCs for a
fixed time periods of 24hrs (acute response), 3 and 7 days. The cytotoxicity was evaluated by
alamarBlue® assay. The hASC live control was cultured on tissue-treated polystyrene and the
dead control was hASC exposed to 70% methanol.
2.4.4. hASCs Exposure to Scaffold Extraction Medias
3mm ht. (height) x 12mm dia. (diameter) composite disks were prepared as above.
Sterilized (ethylene oxide) scaffolds were cultured with 7mL stromal media in 15ml centrifuge
tubes and placed in a rocking incubator at 37°C with moderate shaking for 1, 5, 15 days. The
resultant extraction media from the degradation tests were then added to plated hASCs (2.5 x 104
cells/sample) and cultured for 24hrs to examine acute cytotoxic effects on hASCs. Cell viability
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was evaluated by alamarBlue® assay. The hASC live control was cultured on tissue-treated
polystyrene and the dead control was hASC exposed to 70% methanol.
2.4.5. hASC Loading of PLLA/β-TCP Scaffolds
Scaffold discs of size 12mm dia. x 3mm ht. were seeded with primary hASCs for 1, 5, and
15 days. The scaffolds were sterilized by ethylene oxide. Cells were loaded onto scaffolds
employing a spinner flask reactor (Figure 2.1).

Figure 2.1 Spinner flask assembly
Cells were initially added at approximately 1x105 cells / sample to the reactor and run for
2hrs. The loaded scaffolds were cultured in 12 well plates for 1, 5, and 15 days at 37°C and 5%
CO2. After each time point, the seeded scaffolds were removed out of the culture plate,
transferred to a new plate, and washed with PBS before adding alamarBlue® reagent (10% of
media volume); control: 100% PLLA scaffold.
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2.4.6. Quantitative-PCR (qPCR) of hASC Inflammation and Osteogenesis
Total RNA was isolated from hASCs and hASC loaded scaffolds using TriReagent
(Sigma). Treatment with Turbo DNA-free (Ambion) can be used to eliminate genomic and
plasmid DNA contamination. Quantitative-PCR (qPCR) was performed using iScript One-Step
RT-PCR Kit with SYBR® Green (BioRad) on diluted RNA samples under these conditions
(50°C for 10 min, 95°C for 5 min, 95°C for 10sec, 60°C for 30sec; 40 cycles). Pro-inflammation
up-regulation

was

assessed

using

interleukin-6

(IL-6)

forward

(5’-

CAGAAAACAACCTGAACCTTCCA-3’) and reverse (5’- GGCAAGTCTCCTCATTGAATCC
-3’) [76]on hASCs exposed to particles, media extracts, and cells loaded on scaffolds. Alkaline
phosphatase (ALP) forward (5’- AATATGCCCTGGAGCTTCAGAA -3’) and reverse (5’CCATCCCATCTCCCAGGAA -3’) was used to assess the early osteogenic differentiation of
hASCs exposed to β-TCP particles and cell loaded scaffolds at different time points. Reactions
were performed on a MJ Mini Thermal Cycler (BioRad). IL-6 and ALP expression was
determined by calculating the ΔCt of the samples against the housekeeping gene 18S.
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Results and Discussion
3.1. Scaffold Characterization
3.1.1. Scaffold Morphology and Porosity
Examination of the scaffold morphology and porosity by scanning electron microscopy
showed varying morphological structures in respect to ceramic size and composite composition
(Figure 3.1). β-TCP particle inclusion creates an irregularity in pore structure and construct
morphology [77] (Figure 3.1). The introduction of β-TCP particles perturb the crystallization of
1,4 dioxane [77] resulting in increasing instability and less oriented structures (Figure 3.1).
Increased instability results in an increase in the interconnectivity [36] of the construct which
may improve the suitability of the construct for bone tissue application.

Figure 3.1 SEM of PLLA composites with nano and micro particles. Magnification for all
images: 200X. Composites are identified as %PLLA / % β-TCP. Micro composites: (b-d) and
nano composites: (e-g).
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3.1.2. Thermogravimetric Analysis (TGA)
TGA was used to confirm scaffold blend ratios for each particle size; nano and micro.
Average (n = 3) percent of nano-sized β-TCP was 9.6±1.84, 16.3±3.70, and 30.2±12.70 for
90/10, 70/30, and 40/60 PLLA/β-TCP blends respectively. Average (n = 3) percent of microsized β-TCP was 5.8±0.37, 15.2±0.99, and 23.3±3.17 for 90/10, 70/30, and 40/60 PLLA/β-TCP
blends respectively. TGA results of the various composites reflect that during the freezing
process the particles tend to precipitate out of the polymer matrix of the solution. A solution to
the particle settling may require using a higher molecular weight PLLA along with a reduction in
freezing time.
3.1.3. Differential Scanning Calorimetry (DSC)
DSC is able to provide thermal properties of polymers and polymeric constructs by
monitoring the heat capacity of the material over a temperature range. As the heating progresses,
a noticeable change, a downward shift, in heat capacity occurs over a temperature range. This
downward shift is indicative of the glass transition (Tg). Further heating results in a more orderly
arrangement of the polymer, crystallization, and the crystals begin to give off heat (exothermic)
rather absorbing it (endothermic), the crystallization temperature (Tc). However, heat causes the
polymer to become more orderly, but further heating will result in the crystals to come apart, or
melt, the melting temperature (Tm). A complete plot of heat flow versus temperature would
provide knowledge regarding the thermal properties about the polymer (Figure 3.2).
Table 3.1 shows the thermal transitional temperatures of various PLLA samples. For
reference, a commercially available PLLA (Cargill) and a PLLA from literature (Bastiolli et al)
[43] are included. PLLA in the table represents the PLLA used in fabricating the composite
blends. PLLA (fabrication) and composite blends possess similar Tg and Tm temperatures;
however, there is crystallization due to the semi-crystallinity of the PLLA sample before
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fabrication, which is not present in the fabricated composites because crystallization occurs
during processing.

Figure 3.2. DSC plot of heat flow versus temperature: glass transition temperature (Tg),
crystallization temperature (Tc), and melting temperature (Tm).
Table 3.1. PLLA Thermal Properties
Sample
Tg (°C) DSC Tc (°C) DSC Tm (°C) DSC
Cargill
55
-150.7
Bastiolli et al [43]
61.5
-176.2
PLLA (fabrication)
55.5
98.4
174.5
90/10 composite
56.6
-171.2
70/30 composite
57.6
-172.3
40/60 composite
57.6
-172.4
3.1.4. Mechanical Analysis
To determine the mechanical properties of the nano and micro composite PLLA/ β-TCP
(90/10, 70/30, and 40/60) composite structures, unidirectional compression testing was
performed at a rate of 5mm/min until 50% compressive strain was achieved. Comparison of
composite strengths by scaffold size and blend (Figure 3.2) shows as β-TCP content increases
there is a decrease the compressive stress of the composite. 90/10 composite blends had the
23

highest compressive strengths There are significant effects for particle size (P < 0.05) and
scaffold blend (P <.0001). The results agree with a previous report [65] that the compressive
strength of PLLA/β-TCP scaffold decreases with increasing porosity indicating that the
compressive strength of scaffold with high fraction of β-TCP is lower than that with low fraction
β-TCP.
Polymeric and ceramic composites are generally stronger than bulk polymer constructs
[78] because the ceramic acts as reinforcement. The difference in strengths of the nano-particles
based composites and the micro-particle based composites, may be a result of the decreased
stability during the freezing process. Micro particles cause larger distortions in the freezing
process and result in increased interconnectivity and reduced mechanical strength. The brittle
nature of the calcium phosphates [14, 64, 65] is another contributing factor to the decreased
compressive strengths of composites containing higher percentages of β-TCP particles.

Figure 3.2. Compressive strengths of varying blends of nano vs. micro PLLA/ β-TCP composite
sacffolds. * indicates significance (P < 0.05)
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3.1.5. Scaffold Degradation
15 day degradation study of PLLA/β-TCP composites in stromal media (Figure 3.3)
shows a non-significant (P > 0.05) reduction in percent dry mass. Mass loss was normalized to
the degradation mass of PLLA foam of each respect time point. There was not a significant
change in mass over time due to particle size, but there was a significant effect of blend (P <
0.05) and of particle size by blend (P < 0.05) for the 15 day degradation study. The greatest mass
change was in 40/60 PLLA/ β-TCP blends.
The degradation of PLLA releases acidic degradation products [24, 42] reducing the local
pH; however, (Figure 3.4) indicates pH becoming increasingly basic over time. After 15 day
degradation study, there was a significant effect of degradation time on the pH (P < 0.05).
Incorporation of calcium phosphates, hydroxyapitate (HA) and beta-tricalcium phosphate (βTCP), allow composites to have tunable degradation and absorption kinetics and serve to buffer
the acidic absorption by-products of polymer degradation and could thereby decrease the
deleterious cell response[28]. The CO2 release from solution explains the general increase in pH
in

the

sample

media

over

time

as

shown

in

(Figure

3.4).

Figure 3.3. Scaffold degradation in stromal media after incubation with shaking at 37°C after 1,
5 and 15 days.
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Figure 3.4. pH of degradation medias after incubation with shaking at 37°C after 1, 5 and 15
days. Letters “a-c” indicate significance (P < 0.05) of degradation times.
3.2. In vitro Viability Studies with alamarBlue®
3.2.1. β-TCP Cytotoxicity
hASC viability was determined after exposure to nano and micro β-TCP particles at
varying concentrations: 0.01%, 0.1%, 0.5%, 1.0%, and 2% (%w/v). Viability was determined by
measuring the metabolic activity of hASCs after 1, 3, and 7 day particle exposure (Figure 3.5)
using alamarBlue®. alamarBlue® reagent is a colorimetric/fluorometric indicator of cellular
metabolism and is often used as a viability indicator by measuring the reduction of the active
reagent within living cells. Within the cell, the reagent is reduced resulting in a red color change
and fluorescence. Figures 3.5-3.7 shows the cellular activity of hASCs treated with varying βTCP particle solutions, both for nano and micro-sized particles over a 7 day study with cellular
activity measured at 1, 3 and 7 days. Cell-particle interaction was investigated after 7 day
exposure using light microscopy (Figure 3.8)
1day particle treatment (Figure 3.5) shows micro β-TCP particles to have little cytotoxic
effect on hASCs, whereas cellular viability decreases with increasing nano-particle
concentration. Percent viability (%) of 1 day nano-particle(wt%) treated cells was 86.3%
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(0.01%), 83.7% (0.1%), 96.9% (0.5%), 75.4% (1%), 44.4% (1.5%), 25.3% (2%), and 18.5%
(2.5%), and micro particle viability of 96.2% (0.01%), 106.5% (0.1%), 119.1% (0.5%), 106.0%
(1.0%), 99.0% (1.5%), 126.8% (2.0%), and 107.5% (2.5%). Nano-particles treatments at 3 days
(Figure 3.6) reflect significant (P < 0.05) cytotoxicity at all concentrations above 1%
concentration, and there is minimal cytotoxicity for micro-sized particles. 3 day viability of
nano-particle treated cells was 133% (0.01%), 132% (0.1%), 112% (0.5%), 88% (1.0%), and
essentially zero activity with concentrations above 1%, and average viability of micro-particles
after 3 days was 113% (0.01%), 111% (0.1%), 111% (0.5%), 101% (1.0%), 58% (1.5%), 104%
(2.0%), and 70% (2.5%). 7 day particle treatment (Figure 3.7) showed the highest amount of
particle toxicity for each particle size and concentrations. 7 day viability of nano-particle treated
cells was 59.6% (0.01%), 37.5% (0.1%), 31.1% (0.5%), 20.9% (1.0%), 0.06% (1.5%), 1.0%
(2.0%), and 0.64% (2.5%), and micro particle 62.0% (0.01%), 13.3% (0.1%), 19.9% (0.5%),
35.3% (1.0%), 27.6% (1.5%), 3.3% (2.0%), and 25.2% (2.5%).

Figure 3.5. Viability of hASCs after acute exposure (1 day) to nano and micro particles at
concentrations of 0.01%, 0.1%, 0.5%, 1.0%, 1.5%, 2.0%, and 2.5%. Letters “a” and “b” denote
significant (P < 0.05) difference of particle size.
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Figure 3.6. Viability of hASCs after 3 day exposure to nano and micro particles at
concentrations of 0.01%, 0.1%, 0.5%, 1.0%, 1.5%, 2.0%, and 2.5%. * indicate significant
difference of concentration and “a” and “b” indicate significance of particle size.

Figure 3.7. Viability of hASCs after 7 day exposure to nano and micro particles at
concentrations of 0.01%, 0.1%, 0.5%, 1.0%, 1.5%, 2.0%, and 2.5%. “a” and “b” indicate
significant difference of concentration.
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3.2.2. hASC Exposure to Scaffold Extraction Medias
The subsequent media after scaffold removal is the extraction media. alamarBlue ®assay
was used to measure the viability of acute exposure (1 day) of hASC to the scaffold extraction
medias (Figure 3.9). hASC viability after acute (24hr) exposure to nano composite extracts was
not significantly (P > 0.05) different than the viability of hASCs exposed to micro composite
extracts. The 90/10 composites were significantly different than the PLLA foam control for both
the nano and micro extract treatments. The 40/60 nano composites were significantly different
than the PLLA foam control and the 90/10 nano composites extractions. Micro 40/60 was
significantly (P < 0.05) different than the PLLA foam control, but was not significantly (P >
0.05) different than the 90/10 micro extraction viabilities. The micro extractions, as with the
particles, tend to be less cytotoxic than the nano particles after acute exposure.

Figure 3.9. hASC viability after acute (1 day) scaffold extraction media exposure. Letters “a”
and “b” indicate significant (P < 0.05) difference of composite composition.
3.2.3. hASC Loading of PLLA/ β-TCP Scaffolds
After 2hrs in the reactor, cell loading efficiency was calculated to be 56%.
Approximately 5.0-6.0 x 104 cells were loaded onto each scaffold after the 2hr loading process.
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hASC loaded scaffolds were then cultured for 1, 5 and 15 days. Stromal media was changed
every 5 days. Figure 3.10 shows the viability of the hASCs after being cultured on the composite
scaffolds. Results were normalized to 1 day PLLA to observe the effects of scaffold blends and
how the viability changes over the 15day study. 5 and 15 day cultures are not significantly
different (P > 0.05), but significantly different than the 1 day culture.

Figure 3.10. Viability of hASC loaded nano- and micro-β-TCP scaffolds using a spinner flask
reactor. Approximately 5.0-6.0 x 104 cells loaded onto each scaffold. Cell-scaffolds were
cultured for 1, 5, 15 in stromal media at 37°C and 5% CO2. Letters “a” and “b” indicate
significant (P < 0.05) difference of culture times.
3.2.4. Quantitative-PCR (qPCR) of hASC Inflammation and Osteogenesis
Inflammation is a possible adverse effect of nanoparticle exposure and commonly tested
pro-inflammatory cytokines or protein signals of inflammatory response include IL-1b, IL-6, and
TNF-a plus the chemokine IL-8 [79]. Previously, Kilroy et al [76] showed that
lipopolysaccharide (LPS) exposure increased hASCs secretion of pro-inflammatory
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(interleukins 6, 8, and 11, tumor necrosis factor α) cytokines based on ELISA and RT-PCR.
hASC are known to express osteogenic markers including alkaline phosphatase (ALP),
osteocalcin, osteopontin, and osteonectin in the presence of β-TCP [80]. Aunoble et al [46]
performed in vivo evaluation of inflammatory potential of human osteogenous cells exposed to
PLLA/TCP composite materials containing 0, 30, and 60 (w/w)% TCP with LPS as the positive
control caused less inflammatory reaction. qPCR was used in this study to determine the proinflammatory cytokine (IL-6) and osteogenic (hALP and OCN) response of adipose derived stem
cells resulting from the introduction of β-TCP particles. ΔCt was determined by subtracting the
experimental Ct value from the housekeeping gene (18S) Ct value. If the experimental sample
expresses less of the gene, then its Ct value will be higher resulting in a negative ΔCt.
Figure 3.11 shows the IL-6 (ΔCt) values over 7 days exposure to nano and micro particle
solutions. Particle size and dosage did not have significant impacts on IL-6 expression. IL-6
expression after 7 day exposure was significantly less (P < 0.05) than IL-6 expression after 1 day
exposure.
hASCs acute exposure to nano and micro sized scaffold extractions was quantitatively
analyzed using qPCR for IL-6 expression (Figure 3.12). IL-6 expression was similarly expressed
throughout all samples and results reveal no significant (P > 0.05) impact of the extraction’s
composite composition or for the length of extraction on IL-6 expression. Our findings agree
with a report that ceramic/polymer composites tend to have reduce foreign body response [46].
Reduced IL-6 expression suggests no inflammatory response despite particle dosage or the
length of extraction and extraction composite composition. hALP expression was excluded for
the extraction study, since hALP is an early stage indicator of osteogenesis, but was not
considered to express in hASCs after one day exposure.

32

Expression of IL-6 in cells loaded onto nano and micro composites (Figure 3.13) revealed
a slightly higher expression of IL-6 in the 40/60 composites after 1 day cultivation. After 5 day
cultivation there was not a significant inflammatory response. Overall, there was a noninflammatory response of the hASCs to the nano and micro β-TCP composites. hALP expression
was only monitored for the 5 day cultivation of hASC loaded scaffolds because hALP was not
expected to be expressed as early as the 1 day or as late as the 15 day time points. To assess
intermediate stage osteogenesis, osteocalcin (OCN) expression as was measured after 15 day
hASC cultivation on the composites. hALP and OCN expressions are shown in Figure 3.14.

Figure 3.11. IL-6 expression (ΔCt) of hASCs after 7 days exposure to nano and micro β-TCP
particles. Letters “a” and “b” indicate significance (P < 0.05) in exposure time.

Figure 3.12. IL-6 expression (ΔCt) of hASCs after acute (1 day) exposure to 1, 5, and 15 day
nano and micro β-TCP composite extractions. Letters “a” and “b” indicate significance (P <
0.05).
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Figure 3.13. IL-6 expression (ΔCt) of hASCs after 1 and 5 day cultivation on nano and micro βTCP composite.

Figure 3.14. hALP, early osteogenic marker, and OCN, intermediate osteogenic marker,
expression (ΔCt) of hASCs after cultivation on nano and micro β-TCP composite.
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Conclusion
Calcium phosphates are advantageous in bone composites to address critical size defects.
Because of the lack of information on the effects of particle size, the extent of their benefit as
composite materials remains uncertain. From this research nano and micro β-TCP composite
scaffolds were successfully fabricated using a modified thermally induced phase separation
method with unidirectional freezing and characterized. Scaffolds were not fabricated to meet
needs as load bearing structures, but to assess the effects of varying sized particles in a
composite system. Particle incorporation did improve the mechanical properties, but further
increasing particle content for both nano and micro sized particles resulted in a decrease in
mechanical performance. Micro-particles tend to have better bioactivity, but the reduced
compressive strength in composites makes them unsuitable for structural support. Further studies
of the PLLA/ β-TCP composites with higher polymer content (> 90% PLLA) may yield a better
understanding of the polymer and ceramic interaction in creating a mechanically stable structure.
Particle exposure data indicates hASCs cytotoxicity is initially as a function of particle size
and as exposure time increases cytotoxicity becomes more due to the effects of particle
concentration. Composites with increasing β-TCP content, both nano and micro particles, were
less toxic compared to nano and micro β-TCP particles directly exposed to hASCs. The
difference in viability of particles and composites potentially is that hASCs are exposed to fewer
particles. TGA data revealed that there was a reduction in particle content after fabrication
compared to the initial polymer/ceramic solution and after 15 days of degradation there was not a
significant decrease in mass over time and suggests that polymeric/ceramic systems may reduce
the toxicity of particles. Further studies are needed to better understand the mechanism of
particle cell interaction and possible cellular uptake as visualized in (Figure 3.8). Effectiveness
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of nano based materials is because of their size. Nano particles may provide better cellular
targeting and uptake [79], but there may exist an adverse cellular response to these particles. In
the case of direct particle exposure and hASC viability, micro particles are larger and provide for
better attachment, whereas nano particles are smaller and may be taken in by cells more readily,
which may lead to increased toxicity because of the intake of a foreign material.
Nanocomposite structures also showed increased cytotoxicity to cells based on nanoparticle
content and culture time. As the scaffolds degrade over time, degradation by-products and
particles are released into the media and as more and more products are released into the media,
suggest increased hASC cytotoxic and/or inflammatory response. Our degradation study showed
there was not a significant loss of mass over time for the composites, except 40/60 PLLA/ β-TCP
compositions which had increased mass loss, but only the nano-particle composite extractions
were significantly different than the other composite blend viabilities.
Summarily, the results did show a significant effect of particle size on hASC viability when
directly exposed to cells. Pro-inflammation, IL-6, was relatively nonexistent in the response of
hASC to the various nano and micro particle exposures, as were markers (hALP and OCN) of
osteogenesis. Cells loaded onto composite scaffolds were significantly less toxic compared to
direct nano and micro sized particle exposure. Size additionally played a role in the
morphological and mechanical properties of the fabricated composites. Nano sized particle
composites were significantly stronger than their micro sized counterparts at each composition.
Micro composites tend to be more bioactivity, but their reduced mechanical strengths make the
unsuitable for bone applications. Further studies with the possible inclusion of organic
(cellulosic) and polymeric nanoparticles needed to better understand the mechanism of
particle/cell interaction and their impact on hASCs.
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